Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT00159289
Last Updated: 2024-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2003-06-30
2003-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Markers for Chronic Obstructive Pulmonary Disease (COPD)
NCT00180622
Influence of Electronic Cigarettes in the Evaluation of the Inflammatory Response in Patients With a Diagnosis of COPD
NCT02892396
Biomarkers of iNOS Activity in COPD, Asthma, Healthy Control
NCT00159302
Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
NCT02490358
Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
NCT04598620
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Inhalation of LPS
Inhalation of LPS
2
PLacebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inhalation of LPS
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 0: At risk (current or ex-smokers): normal spirometry, with or without chronic symptoms (cough, sputum production)
* I-II: Mild-moderate COPD
* FEV1 reversibility of \< 15% after inhaled beta2-agonists
* FEV1/forced vital capacity (FVC) \< 70% predicted
* FEV1 between greater than or equal to 50% and less than 80%
* With or without chronic symptoms (cough, sputum production)
* Able to comprehend and grant a written informed consent
Exclusion Criteria
* Respiratory infection within 4 weeks prior to entry into the trial
* Females who are pregnant or lactating
* History of current or past drug or alcohol abuse
21 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sergei A Kharitonov, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Imperial College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2002AT032B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.